How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice?

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 2, 1996, Pages 437-442

  Ji, Baohong ^a   Lounis, Nacer ^a   Truffot Pernot, Chantal ^a   Grosset, Jacques ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAMYCIN DERIVATIVE; RIFAPENTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIOSTASIS; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MIXTURE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; PRIORITY JOURNAL; SPLEEN;

EID: 0030034824     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.2.437     Document Type: Article

References (26)

1. Bermudez, L. E., P. Kolonoski, L. S. Young, and C. B. Inderlied. 1994. Activity of KRM 1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection. Antimicrob Agents Chemother. 38:1844-1848.
2. Betram, M. A., C. B. Inderlied, S. Yadegar, P. Kolanoski, J. P. Yamada, and L. S. Young. 1986. Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex J Infect. Dis. 154:194-195.
3. Doucet-Populaire, F., C. Truffot-Pernot, J. Grosset, and V. Jarlier. 1996. Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin J. Antimicrob Chemother. 36:129-136.
4. Emori, M., H. Saito, K. Sato, H. Tomioka, T. Setogawa, and T. Hidaka. 1993. Therapeutic efficacy of the benzoxazmorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits. Antimicrob. Agents Chemother. 37:722-728
5. Fernandas, P. B., D. J. Hardy, D. McDaniel, C. W. Hanson, and R. N. Swanson. 1989. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob. Agents Chemother. 33:1531-1534.
6. Fujii, K., H. Saito, H. Tomioka, T. Mae, and K. Hosoe. 1995. Mechanism of action of antimycobacteriol activity of the new benzoxazinorifamycin KRM-1648 Antimicrob. Agents Chemother 39:1489-1492.
7. Fujii, K., A. Tsuji, S. Miyazaki, K. Yamaguchi, and S. Goto. 1994 In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. Antimicrob. Agents Chemother. 38:1118-1122.
8. Gangadharam, P. R. J., C. K. Edwards III, P. S. Murthy, and P. F. Pratt. 1983. An acute infection model for Mycobacteriumn intracellulare disease using beige mice. Preliminary results. Am Rev Respir. Dis. 127:468-169.
9. Gangadharam, P. R. J., V. X. Perumal, B. T. Jairam, P. N. Rao, A. K. Nguyen, D. C. Farhi, and M. U. Iseman. 1987 Activity of rifabutin alone or in combination with clofazimme or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections Am. Rev. Respir. Dis. 136:329-333.
10. Grosset, J. 1978. The sterilizing value of rifampicin and pyrazinamide in experimental short course chemotherapy. Tubercle 59:287-297.
11. Grosset, J. H., C. Truffot-Pernot, J. Fermanian, and H. Lecoeur. 1982 Activité stérilisante des differents antibiotiques dans la tuberculose expérimentale de la souris. Pathol. Biol. 30:444-448.
12. Heifets, L., N. Mor, and J. Vanderkolk. 1993 Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob. Agents Chemother. 37:2364-2370
13. Inderlied, C. B., L. Barbara-Burnham, M. Wu, L. S. Young, and L. E. Bermudez. 1994 Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages Antimicrob Agents Chemother. 38:1838-1843.
14. Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1992. Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy. Antimicrob. Agents Chemother. 36:2839-2840.
15. Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1994 Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob. Agents Chemother 38:2521-2529.
16. Ji, B., C. Truffot-Pernot, C. Lacroix, M. C. Raviglione, R. J. O'Brien, P. Olliaro, G. Roseigno, and J. Grosset. 1993. Effectiveness of rifampin, rifabutin and rifapentine for preventive therapy of tuberculosis in mice. Am Rev. Respir. Dis. 148:1541-1546.
17. Klemens, S. P., and M. H. Cynamon. 1991. In vivo activities of newer rifamycin analogs against Mycobacterium avium infection. Antimicrob. Agents Chemother. 35:2026-2030
18. Klemens, S. P., and M. H. Cynamon. 1992 Activity of rifapentine against Mycobacterium avium infection in beige mice J. Antimicrob Chemother 29:555-561
19. Klemens, S. P., M. A. Grossi, and M. H. Cynamon. 1994. Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex. Antimicrob Agents Chemother. 38:234-237.
20. Klemens, S. P., M. A. Grossi, and M. H. Cynamon. 1994. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 38:2245-2248.
21. Lounis, N., B. Ji, C. Truffot-Pernot, and J. Grosset. 1995. Selection of clarithromycin-resistant Mycobacterium avium complex during combined therapy using the beige mouse model. Antimicrob. Agents Chemother. 39: 608-612.
22. Saito, H., H. Tomioka, K. Sato, M. Emori, T. Yamane, K. Yamashita, K. Hosoe, and T. Hidaka. 1991. In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrob. Agents Chemother. 35:542-547.
23. Tomioka, H., H. Saito, K. Fujii, K. Sato, and T. Hidaka. 1993. In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method. Antimicrob. Agents Chemother. 37:67-70.
24. Tomioka, H., H. Saito, K. Sato, T. Yamane, K. Yamashita, K. Hosoe, K. Fujii, and T. Hidaka. 1992 Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin. KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrob. Agents Chemother 36:387-393.
25. Wong, B., F. F. Edwards, T. E. Kiehn, E. Whimbey, H. Donnelly, E. W. Bernard, J. W. W. Good, and D. Armstrong. 1985. Continuous high-grade Mycobacterium avium-intracellulare bacteremia in patients with the acquired immune deficiency syndrome. Am. J. Med. 78:35-40.
26. Yamane, T., T. Hashizume, K. Yamashita, E. Konishi, K. Hosoe, T. Hidaka, K. Watanabe, H. Kawaharada, T. Yamamoto, and F. Kuze. 1993. Synthesis and biological activity of 3′-hydroxy-5′-aminobenzoxazinorifamycin derivatives. Chem. Pharm. Bull. 41:148-155.